Brought to you by 
Retrophin makes unsolicited offer to acquire CNS-focused Transcept; withdrawn
18 Dec 2013
Executive Summary
Retrophin Inc. (orphan disease treatments) has made a formal public proposal to acquire publicly traded CNS firm Transcept Pharmaceuticals Inc. for $4.00 per share, a 27% premium. Retrophin already owns 4.9% of Transcept's stock.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Intra-Biotech Deal
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Retrophin makes unsolicited offer to acquire CNS-focused Transcept; withdrawn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice